Pearson B S, Raghavan D
Br J Urol. 1985 Dec;57(6):690-3. doi: 10.1111/j.1464-410x.1985.tb07033.x.
Seventy patients with T2-T4 NX MO bladder cancer were treated with intravenous cisplatin (100 mg/m2 q 3-weekly) followed by radiotherapy and/or cystectomy. Objective responses to cisplatin were seen in 57%. For the first group of 50 patients (treated between August 1981 and November 1983), the actuarial survival rate at 2 years was 64%, with a median survival of 20+ months: 81% of deaths occurred within 18 months of entry. Most relapses occurred in the bladder/pelvis. A randomised, controlled study is in progress to assess the true value of this approach to the treatment of invasive bladder cancer.
70例T2 - T4 NX MO期膀胱癌患者接受了静脉注射顺铂治疗（100 mg/m²，每3周一次），随后进行放疗和/或膀胱切除术。57%的患者对顺铂有客观反应。对于第一组50例患者（1981年8月至1983年11月接受治疗），2年的精算生存率为64%，中位生存期为20多个月：81%的死亡发生在入组后的18个月内。大多数复发发生在膀胱/盆腔。一项随机对照研究正在进行中，以评估这种治疗浸润性膀胱癌方法的真正价值。
